Celgene: Q3 2015 Earnings Conference Call (Celgene) - Nov 8, 2015 - Anticipated completion of enrollment in P1 CD-001 trial (NCT02367183) for Crohn’s disease by end of 2015; Anticipated initiation of patient randomization in P3 CD-002 trial (NCT02596893) for Crohn's disease in Q4 2015; Anticipated initiation of registration trial CD-003 for Crohn’s disease in H1 2016; Anticipated initiation of proof-of-concept P2 trial in ulcerative colitis in Q4 2015
Anticipated enrollment status • Anticipated new P2 trial • Anticipated new trial • Trial status • Inflammatory Bowel Disease
|